Document:

Development Agreement with Alan S. Hilibrand

 Exhibit 10.39 
  
 EXECUTION COPY 
  
 DEVELOPMENT AGREEMENT 
  
 This Development Agreement (this “Agreement”) is made and entered into as of the 8th day of September, 2005 (the “Effective Date”), by
and between AMEDICA CORP., a Delaware corporation (“Amedica”), and Alan S. Hilibrand, M.D. (“Hilibrand”). 
  
  
 RECITALS: 
  
 A. Amedica is in the business of designing, developing and selling various products and applications for medical and
biomedical uses that are made from various materials, including advanced ceramic materials. 
  
 B. Amedica desires to continue to encourage, through collaboration among two or more developers (“Collaborators”), the development, testing and clinical training for novel Devices (as defined herein) for
implant in or use with the spine in medical and surgical procedures , whether manufactured from ceramic materials or other materials. 
  
 C. Hilibrand offers clinical knowledge and experience relating to the spine. 
  
 D. The parties desire to enter into an agreement to assist in the future development, approval, trial and clinical use of
Devices. 
  
 NOW, THEREFORE, for and in consideration of the
mutual promises and covenants herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree and represent as follows: 
  
 1. Definitions. For purposes of this Agreement, the following
terms shall have the following definitions: 
  
 a. “Development Services” means the development and related services as requested by Amedica relating to the conceptualization, development, testing, approval and related matters involving the Devices more fully described in
Section 2, below. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. “Devices” means all ideas, discoveries, creations, improvements, know-how,
inventions, designs, developments, apparatus, techniques, methods, processes, and materials, whether or not patentable, including all rights to obtain, perfect or enforce any proprietary interests therein, in the Field of Interest, which Hilibrand,
whether alone or in concert with others, may conceive, reduce to practice or develop during the Term (or, if based on or related to any confidential or proprietary information of Amedica, within [***********] after the termination of this
Agreement), alone or in conjunction with another, or others, whether during or out of regular business hours, and whether at the request or upon the suggestion of Amedica, or otherwise. These Devices include but are not limited to those items more
fully identified on Schedule A attached hereto. 
  
 c. “Field of Interest” means the development, testing and commercializing of biomedical or surgical devices, covered by current Amedica patent applications and further Amedica developments, and utilizing ceramic materials,
intended for use in diagnosing, preventing or treating diseases or conditions affecting the spine or related structure or tissues or any applications thereof. Amedica may expand or otherwise change the definition of its Field of Interest at any
time, as long as this expansion continues to be related solely to ceramic materials, which new definition will be binding upon Hilibrand ten (10) days after written notice to Hilibrand thereof. 
  
 d. “Collaborators” refer to the list of
professionals more fully identified on Schedule B attached hereto. 
  
 2. Cooperative Development Arrangements. The parties intend that Hilibrand, in collaboration and cooperation with the Collaborators shall diligently perform the Development Services which shall include, without limitation, the
following 
  

 2 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 a. Examining and reviewing the characteristics of the Devices and the nature of the
materials with which the Devices are constructed. 
  
 b. Offering experience on ideas and testing pertaining to the Devices, and coordinating with other Amedica personnel and third parties related to such testing, as requested by Amedica. 
  
 c. Providing guidance and assistance in the clinical details
of the Devices. 
  
 d. Assisting in the filing of
provisional patents and other patents pertaining to the Devices as determined by Amedica. 
  
 e. Assisting in applying for or otherwise seeking regulatory approval for the Devices or surgical processes for their implantation or
other use. 
  
 3. Term and Termination. 

 
 a. The term (the “Term”) of this Agreement
shall commence as of the Effective Date and shall continue until the later of: (i) ten (10) years from the date hereof; or (ii) the expiration of the final remaining patent rights on the last of the Devices, unless earlier terminated
as provided hereunder. 
  
 b. Either party has
the right to terminate this Agreement at any time upon thirty (30) days’ prior written notice thereof to the other party. If either party terminates this Agreement pursuant to this subsection 4(b), Amedica shall be obligated to continue to
pay royalty payments that are earned for Devices resulting from Hilibrand’s Development Services. 
  
 c. The parties acknowledge that Amedica has entered into agreements with other Collaborators, listed on Exhibit “B,” attached
hereto, which agreements contain the same material provisions contained in this Agreement. Those other agreements and this 

  

 3 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
Agreement, which are intended to be performed in cooperation with each other, are referred to herein as the “Collaboration Agreements.” Upon the
death or termination of a Collaborator other than Hilibrand (or Hilibrand’s entity, as applicable) this Agreement shall continue (subject to Subsection 4(b) above) as to Hilibrand and all remaining Collaborator(s); provided, that Hilibrand
agrees, as soon as reasonably possible, to negotiate in good faith with the remaining Collaborators any modifications to Hilibrand’s duties and compensation as may be appropriate under the circumstances. 
  
 4. Compensation for Assignment and Sale Proprietary Rights. As
full consideration for the Development Services and any valuable assignment of rights in or related to Devices to Amedica pursuant to Section 9 hereof, Amedica shall pay Hilibrand the total of the following: 
  
 a. Hilibrand shall, in the form of royalty or similar
payments, receive the total of up to [**************] of the Net After-Tax Profits as separately agreed upon by Hilibrand and Amedica; provided, that this is subject to the provisions of Subsections 4(c) and 4(d) below. “Net After-Tax
Profits” is defined as that portion of profits received by Amedica attributable to sale of Devices, after deducting from all gross proceeds from such sales the costs and expenses attributable to the development, testing, marketing and sale of
the Devices (but not including any Amedica overhead or expenses unrelated to the Devices), and less all sales, use, occupation or excise taxes and all income taxes applicable to income generated from the Devices. 
  
 b. Hilibrand’s respective share of the Net After-Tax
Profits may be modified by Hilibrand and Amedica, in good faith, based upon Hilibrand’s contribution to the final form of the Devices, relative to the contributions of Amedica, other Collaborators and any third parties. Such share shall be
calculated on a monthly basis, with payment to Hilibrand of each monthly amount no later than the last day of the following month. 
  

 4 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 c. Upon Hilibrand’s death, or upon letters from two independent physicians that
Hilibrand is permanently disabled and unable to perform the nature of the Development Services hereunder, this Agreement shall terminate as to Hilibrand; provided, that Hilibrand (or Hilibrand’s surviving spouse or estate), or Hilibrand’s
entity, as applicable, shall continue to be entitled to receive the royalties as provided herein. 
  
 d. Notwithstanding any provision herein to the contrary, income used for calculating royalties payable to Hilibrand hereunder shall not
include any sales attributable to the use of any Devices by any hospital or surgical center where Hilibrand, or any entity controlled by Hilibrand currently practices medicine or contracts for services. 
  
 No provision under this Agreement, either overtly or covertly, directly or
indirectly, requires or contemplates that Hilibrand make any recommendations to Hilibrand’s patients or health care facilities with respect to Amedica’s Devices or other products. There shall be no adjustment to the percentage of
royalties, or the rate of any other compensation, if any, resulting from the presence of or absence of, any recommendations of Amedica’s Devices or other products to Hilibrand’s patients or health care facilities by Hilibrand. 

 
 If Hilibrand is paid any share of Net After Tax Profits inconsistent with
the provisions of this Subsection 4(d), upon advance written notice to Hilibrand, Amedica will offset such improperly paid amount from any future payment owing to Hilibrand. 
  
 e. Amedica shall maintain separate and sufficient accountings and records relating to the Devices to enable
the payments payable hereunder to be determined and 

  

 5 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
verified. Hilibrand shall, at all times, have reasonable access to examine Amedica’s books and records relating to the Devices. The parties shall
promptly reconcile any payment discrepancies discovered through any such audit. 
  
 f. Without limiting the provisions of Subsection 4(c), the parties acknowledge that the continued payment of, and the continuing
obligation to pay, the royalties payable hereunder is not dependent on the continuing performance of the Development Services, the ongoing Term of this Agreement, or any other contingency or condition, except as expressly provided to the contrary in
Subsection 4(b). 
  
 g. Hilibrand acknowledges
that the payment provisions of this Section 4 represent the sole agreement between the parties with regard to Hilibrand’s compensation for all Development Services and any assignment of rights to the Devices; and Amedica shall not be
obligated to make, or otherwise be liable for, any additional payment of compensation or reimbursement of expenses with regard to Development Services or the Devices or other similar type payment. It is the parties’ intent that this Agreement
provide for the “sale or exchange of a capital asset” by Hilibrand to Amedica under Internal Revenue Code Section 1235 entitled “Sale or Exchange of Patents,” and that all payments made to Hilibrand hereunder shall be taxed
as long-term capital gains. Nothing in this Agreement to the contrary shall imply that the parties intend that the payments to Hilibrand hereunder shall be for anything other than the transfer of all proprietary rights that Hilibrand may have in the
Devices. Amedica is making no warranties or representations, however, as to ultimate taxability of the payments to Hilibrand hereunder. 
  

 6 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 5. Facilities. To the extent necessary, Amedica shall provide Hilibrand with office space,
equipment, telephone, secretarial help and all other equipment and related services necessary for the performance of the Development Services hereunder. 
  
 6. Exclusivity. Amedica acknowledges that Hilibrand, and any entities which may currently or in the future be controlled by Hilibrand, have
other professional business and investment dealings in addition to his responsibilities under this Agreement and that Hilibrand will not be required to devote his time exclusively to his responsibilities hereunder, either directly or indirectly.
Notwithstanding any provision herein to the contrary, Hilibrand agrees that during the Term, as between Hilibrand and Amedica, Amedica shall possess the exclusive ownership of the Devices. Amedica acknowledges that this is a non-exclusive agreement,
and nothing herein may be construed to prohibit either Amedica or Hilibrand from entering into similar contractual relationships with other parties, or from engaging or participating in any other venture, unrelated to the Devices. Without limiting
the foregoing, Amedica recognizes and acknowledges that Hilibrand (either directly or though his entities) actively performs consulting and product development services for and on other parties in the area of neurosurgery and related fields;
therefore, Hilibrand may provide consulting, product development, and other services, not related to the Devices, for and on behalf of persons or entities that may compete with Amedica or that develop, manufacture, or sell products or technologies
that are similar in function or design (excluding the Field of Interest, which involves solely ceramic materials) to those developed or sold by Amedica. 
  
 7. Confidentiality. 
  
 a. Both during the Term and following termination of this Agreement for any reason, except as necessary for the performance of the
Development Services hereunder, 

  

 7 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
Hilibrand shall not, at any time or in any manner, directly or indirectly, use, divulge, disclose or communicate to any third-person or entity any
information that was disclosed to or developed by Hilibrand during the course of performing the Development Services and which is not (i) information that Hilibrand was aware of prior to the term of this Agreement, (ii) information that
Hilibrand becomes aware of through a source other than Amedica, (iii) information that is available to the general public through a prior disclosure, provided that Hilibrand did not commit such prior disclosure in violation of this Agreement,
or (iv) the Retained Intellectual Property (as defined herein). Also without limiting the foregoing, Hilibrand may disclose the existence and general nature of this Agreement and the fact that it pertains to the Development Services and the
Devices. Subject to the foregoing exceptions, the confidential information described herein shall include information regarding matters affecting or relating to Amedica’s business or its Devices; the nature of Amedica’s properties or
products, whether developed or under development; the identity of Amedica’s customers; prices which Amedica obtains or has obtained with respect to its products or services; information as to Amedica’s discussions, negotiations and/or
dealings with actual or potential third-party buyers, investors, licensees or co-venturers; Amedica’s costs, overhead or profit margin; or Amedica’s operational methods or its business plans and processes. 
  
 b. Promptly following termination of this Agreement,
Hilibrand shall deliver to Amedica any and all property of Amedica which may be in his possession including products, materials, memoranda, notes, records, reports, writings, drawings, diskettes, models and other materials or other documents or
photocopies of the same in any tangible form whatsoever constituting confidential or proprietary information of Amedica, and any of the foregoing in intangible form. 
  

 8 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 8. Covenant Not to Compete. 
  
 a. Hilibrand recognizes and acknowledges the competitive and proprietary nature of Amedica’s Field of
Interest. Hilibrand acknowledges and agrees that a business will be deemed competitive with Amedica if it develops, manufactures or sells any ceramic products within the Field of Interest and Hilibrand has participated in the creation, research
and/or testing of those such ceramic products (such business to be referred to as a “Competitive Business”). 
  
 b. Hilibrand agrees that during the Term and for an additional [**********] after termination of this Agreement (which period shall
be tolled during the period of any violation or breach of any of the provisions hereof and for a period of [**********] thereafter), whether such termination is voluntary or involuntary, Hilibrand shall not: 
  
 (i) for his benefit, or on behalf of any other person or
entity, directly or indirectly, as principal, agent, stockholder, employee, consultant, representative or in any other capacity, own, manage, operate or control, or be concerned, connected or employed by, or otherwise associate in any manner with,
engage in or have a financial interest in any Competitive Business anywhere in the continental United States of America (the “Restricted Territory”), except that nothing contained herein shall preclude Hilibrand from purchasing or owning
securities of any such business if such securities are publicly traded, and provided that his holdings do not exceed one percent (1%) of the issued and outstanding securities of any class of securities of such business; or 
  

 9 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 (ii) either individually or on behalf of or through any third party, directly or
indirectly, solicit, entice or persuade or attempt to solicit, entice or persuade any other employees of or consultants to Amedica or any present or future parent, subsidiary or affiliate of Amedica to leave the services of Amedica or any such
parent, subsidiary or affiliate for any reason. 
  
 c. Hilibrand further recognizes and acknowledges that: (i) the restrictions in this Section 8 are reasonable in relation to the skills which represent his principal salable asset both to Amedica and to any prospective employers,
and (ii) the geographical scope of the provisions of this Section 8 is reasonable, legitimate and fair to Hilibrand in light of Amedica’s need to market its services and sell its products worldwide in order to have a sufficient
customer base to make Amedica’s business profitable and in light of the limited restrictions on the type of employment prohibited herein compared to the types of employment for which Hilibrand is qualified to earn his livelihood. 
  
 d. The acknowledgments and agreements set forth in this
Section 8 shall survive the termination of Hilibrand’s performance of the Development Services for any reason, for the time period set forth herein. 
  

9. Ownership of Ideas, Copyrights and Patents. 
  

a. Hilibrand agrees that he will take reasonable steps to promptly disclose all Devices to Amedica and that he will not publish any
Devices, or any information with regard thereto, without the prior written consent of Amedica, which will not be unreasonably withheld. 
  
 b. As between Hilibrand and Amedica, Amedica shall have the sole and exclusive right, even as to Hilibrand, to prepare, file, prosecute,
obtain and maintain any 

  

 10 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
and all patents and patent applications claiming any Devices. All Devices shall be the sole and exclusive property of Amedica and, subject to payment
pursuant to the provisions of Section 3 hereof, and the waivers of any and all representations and warranties concerning the Devices as set forth in Subsection 9(e) below, Hilibrand hereby assigns to Amedica all of his right, title and interest
in and to all of the Devices, including the intellectual property therein, which may include trade secrets, inventions, discoveries, or improvements, whether or not registerable or patentable, that are conceived, whether alone or jointly with
others, during the Term of this Agreement that are a direct and specific result of the Development Services (collectively, the “Assigned Intellectual Property). This assignment does not include any such intellectual property that pertains : to
(i) neurosurgical principles in general (including products that may pertain to the same pathological conditions in the same anatomical locations that are relevant to the Devices; to (ii) other products or technologies used in
neurosurgery; (iii) to proprietary concepts and inventions in which Hilibrand has any right, title, or interest as of the date of the execution of this Agreement (collectively “Prior Rights”), or (iv) to any other concept,
know-how, discovery, or other intellectual property that is not within the definition of the Assigned Intellectual Property (all of the foregoing collectively, the “Retained Intellectual Property”). Hilibrand shall not be restricted from
assigning, licensing, or otherwise utilizing the Retained Intellectual Property in any manner. 
  
 c. Hilibrand hereby agrees to reasonably cooperate with Amedica, its attorneys and agents in the preparation and filing of all papers and
other documents as may be required to perfect Amedica’s rights in and to any Devices, including, but not limited to, performing all acts reasonably deemed necessary or desirable by Amedica 

  

 11 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
(both during the Term and for a period of [***********] after expiration of this Agreement) and joining in any proceeding to obtain letters patent,
copyrights, trademarks or other legal rights of the United States of America and of any and all other countries to Devices; provided, that, Amedica will bear the expense of all such proceedings. Hilibrand hereby agrees that any patent or other legal
right covering any Assigned Intellectual Property issued to Hilibrand, shall be assigned by Hilibrand to Amedica without charge. 
  
 d. Without limiting the foregoing, Hilibrand further acknowledges that all original works of authorship made by such Hilibrand, within the
Field of Interest, by Hilibrand that Hilibrand has first conceived and first reduced to writing, whether alone or jointly with others during the Term of this Agreement that are a direct and specific result of the Development Services and that are
protectable by copyright are “works made for hire” within the meaning of the United States Copyright Act, 17 U.S.C. § 101, as amended, the copyright of which shall be owned solely, completely and exclusively by Amedica. If any such
work is not considered to be a work made for hire covered by the United States Copyright Act, 17 U.S.C. § 101, as amended, such work shall be owned solely by, or hereby assigned or transferred completely and exclusively to, Amedica. Any and all
works of authorship described in this Subsection shall be included within the definition of Assigned Intellectual Property. 
  
 e. Notwithstanding anything herein to the contrary, Hilibrand expressly disclaims, and Amedica expressly waives, any and all
representations and warranties in regard to or concerning the Assigned Intellectual Property, the Development Services and the Devices. Without limiting the foregoing, the parties agree that Hilibrand does not represent or warrant that any portion
of the Assigned Intellectual Property is valid, 

  

 12 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
enforceable, registerable, or original, that it will be free from claims of infringement, interference, or unlawful use of proprietary information of any
third party, or that it does not infringe upon the intellectual property rights of any other party. Furthermore, Hilibrand expressly disclaims, and Amedica expressly waives, the warranties of merchantability and fitness for a particular purpose with
regard to the Assigned Intellectual Property, the Development Services and the Devices, and any and all representations and warranties that the Assigned Intellectual Property and the Devices will perform or function in any particular manner, with
any particular results, or free from defects. 
  
 10.
Representations and Warranties Regarding Prior Work and Legal Obligations. 
  
 a. Hilibrand hereby represents and warrants that he has no commitments or obligations with any prior employer or any other person or
entity that, would restrict his ability to perform the Development Services 
  
 b. Hilibrand represents that he has been advised by Amedica that at no time should he divulge to, or use for the benefit of, Amedica any trade secret or confidential or proprietary information of any previous
employer. Hilibrand acknowledges that he has not divulged or used any such information for the benefit of Amedica. 
  
 c. Hilibrand acknowledges that Amedica is basing important business decisions on these representations, and affirms that all of the
statements included herein are true. 
  
 11. Equitable
Remedies. Hilibrand acknowledges that the breach of the provisions of Sections 7, 8, 9 and 10 above shall constitute irreparable damage to Amedica and, 

  

 13 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
accordingly, Amedica may, in addition to all other available remedies under law and equity, obtain injunctive relief upon an alleged violation of such
Sections pending resolution on the merits of any claims raised by Amedica hereunder. 
  
 12. Stock Option Arrangements. As further consideration hereunder, the parties agree in good faith to negotiate an agreement granting Hilibrand, or Hilibrand’s designate, certain rights to obtain
options for the purchase of Amedica stock. The nature, amount and terms of such options shall be agreed upon by the parties in good-faith as soon as reasonably possible. 
  
 13. Development Agreement Only. This Agreement constitutes a development agreement only. Nothing herein is
intended, nor shall it be construed, to create any employer/ employee arrangement, partnership arrangement or other relationship between or among the parties except as expressly provided herein; and nothing herein is intended to grant to either
party any right or interest in or to the assets, business or interests of the other party, nor the right to bind the other party except as expressly herein provided. 
  
 14. Compliance with Laws and Regulations. The parties, at all times, shall interpret and apply the provisions
of this Agreement strictly in accordance with all applicable laws and regulations, including, but not limited to all Medicare and Medicaid laws and regulations. 
  

If any provision of this Agreement is found, by any applicable court or government agency, to be in conflict with any applicable law or regulation, the
provisions of such law or regulation shall govern; and the interpretation and operation under this Agreement shall be modified accordingly. 
  
 The parties have no intent through this Agreement or otherwise to solicit, receive, offer, or pay any remuneration in return for recommending the use or
utilization of any good or service 

  

 14 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
payable under certain federal health programs, as such is prohibited by the statute at 42 U.S.C. 1320a-7b(b), nor do the parties have any other impermissible
intent to violate any similar federal or state law that may apply with regard to any other health care reimbursement program. Hilibrand is under no obligation whatsoever to utilize any products manufactured by Amedica, nor to recommend that such
products are utilized by others. If any provision of this Agreement is determined by either party to present a possible violation of any such law, as supported by a written, reasoned opinion of competent legal counsel, the parties shall in good
faith negotiate together to amend the terms of this Agreement in a manner that will alleviate any such possible violation while preserving the reasonable business (e.g., compensation) expectations of the parties. 
  
 15. Indemnification by Amedica. 
  
 a. Amedica will indemnify and hold Hilibrand harmless from
any and all claims, costs, judgments and expenses involving (i) any claim that any Device infringes or interferes with any patent or other proprietary claim of any third-party, and (ii) to the extent claimed or proven to be solely due to
Device design or manufacturing defect (including reasonable attorneys’ fees) of whatever sort based on claims of product design or manufacturing defects whether sounding in negligence, strict liability at law, contract or statutory violation,
and (iii) any breach by Amedica of any provision of this Agreement. 
  
 b. Any indemnification provided by Amedica hereunder shall not apply to any claim insofar as that claim (i) relates to a professional medical liability or malpractice claim brought against Hilibrand for
professional acts or omissions in connection with the medical care or treatment associated with a Device; (ii) arises from any breach by 

  

 15 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
Hilibrand of any provision of this Agreements; or (iii) arises from any knowing submission by Hilibrand of false data to Amedica or from any other
intentional wrongdoing by Hilibrand. 
  
 c.
Promptly upon Hilibrand’s receipt of information concerning the commencement of any third-party claim, demand, action, suit or proceeding (collectively, “Action”) which is the subject of indemnification hereunder, Hilibrand shall
notify Amedica in writing of the commencement of the Action. Any failure to provide such prompt notice shall relieve Amedica of its indemnification obligations to the extent Amedica has been materially prejudiced by such failure. Amedica may select
counsel at its own expense and control the defense of such indemnity claim; and Hilibrand may participate jointly with Amedica in such defense, at Hilibrand’s expense, in which event the parties shall reasonably cooperate with each other.
Amedica will vigorously defend any such claim, and shall not settle any such claim or refrain from appealing any adverse ruling, judgment, or verdict without the advance written consent of Hilibrand, which consent shall not be unreasonably withheld.
With respect to any Action relating solely to the payment of money damages, Amedica shall have the sole right to defend, settle, or otherwise dispose of such claim on such terms as Amedica, in its sole discretion, shall deem appropriate; provided,
that Amedica shall provide reasonable evidence of its ability to pay any damages claimed. If the Action involves any claim in which Hilibrand would become subject to injunctive relief or to other equitable relief, or Hilibrand’s business would
be adversely affected in any manner, Amedica shall settle that claim only upon the written consent of Hilibrand, which shall not be unreasonably withheld. 
  

 16 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 16. Indemnification by Hilibrand. Except to the extent that any such claims arise through
the wrongful act or neglect of Amedica, Hilibrand will indemnify and hold Amedica harmless from any and all claims, costs, judgments and expenses arising from any breach by Hilibrand of any warranty, representation or affirmative obligation of
Hilibrand under this Agreement. 
  
 17. General.

  
 a. Notices. All notices required
or permitted to be given to a party hereunder shall be mailed by certified mail or registered mail, postage prepaid, to that party’s address set forth on the signature page of this Agreement (or to such other address specified in writing).

  
 b. Default. If either party defaults
in any of the covenants or provisions herein, the defaulting party shall pay all costs and attorneys’ fees incurred by the other party in enforcing its rights arising hereunder. Hilibrand shall be provided with a copy of any notice given to
Hilibrand hereunder: 
  
 c. Governing Law and
Venue. This Agreement shall be interpreted, performed and enforced according to the laws of Utah. Venue for any action hereof shall lie with the Third Judicial District Court of the State of Utah for the United States District Court for the
District of Utah, Central Division. 
  
 d.
Unenforceable Provision. If any provision of this Agreement is deemed unenforceable by any court of competent jurisdiction, the remaining provisions shall nonetheless be enforceable according to their terms. Further, if any provision is held
to be over broad as written, such provision shall be deemed amended to narrow its application to the extent necessary to make the provision enforceable according to applicable law and shall be enforced as amended. 
  

 17 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 e. Assignment. Amedica may assign its rights and obligations hereunder to any
person or entity that succeeds to all or substantially all of Amedica’s business or that aspect of Amedica’s business in which Hilibrand is principally involved. Hilibrand’s rights and obligations under this Agreement may not be
assigned by that Hilibrand without the prior written consent of Amedica. 
  
 f. Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and
permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except between the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this Agreement,
other than any future parent, subsidiary or affiliate of Amedica. 
  
 g. Entire Agreement. This Agreement embodies the entire agreement and understanding between and among the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written
agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the
express terms and provisions of this Agreement. 
  
 h. Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto. 
  

 18 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 i. Waivers and Consents. The terms and provisions of this Agreement may be waived,
or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect
to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or
consent. 
  
 j. Construction. The parties
have participated equally in the formation of this Agreement and the language of this Agreement will not be presumptively construed against either party. 
  
 k. Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 l. Section Numbers and Headings. The Section and. Subsection headings and numbers used herein are for purposes of convenience and
shall not be considered in the interpretation of this Agreement. 
  

 19 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF this 8th day of September, 2005. 
  

					
		 	AMEDICA
		
	ADDRESS:	 	AMEDICA CORP.
		 	A DELAWARE CORPORATION
			
	Amedica Corporation	 		 	
	615 Arapeen Drive, Suite 302	 	By:	 	 /s/ Ashok Khandkar

	Salt Lake City, UT 84108	 	Its:	 	President and CEO
		
		 	HILIBRAND
	ADDRESS:	 		 	
			
	Alan Hilibrand, M.D.	 		 	
	[********************]	 	 /s/ Alan Hilibrand, M.D.

	[********************]	 	ALAN HILIBRAND, M.D.

  

 20 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

  
 SCHEDULE A 

 
 Devices 
  
 The Devices consist of the following: 
  

	 	1.	 	[**************] 

  

	 	2.	 	[**************] 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

  
 SCHEDULE B 

 
 List of Collaborators 
  

	 	[1]	 	[**************] 

  

	 	[2]	 	[**************] 

  

	 	[3]	 	[**************], and 

  

	 	[4]	 	[**************] 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended.Development Agreement with Rodney Plaster

 Exhibit 10.40 
  
 EXECUTION COPY 
  
 DEVELOPMENT AGREEMENT 
 BETWEEN
AMEDICA CORPORATION AND RODNEY PLASTER, M.D. 
  
 This Development Agreement (this “Agreement”) is made and entered into as of the
12th day of December, 2005 (the “Effective Date”), by and between AMEDICA CORP., a Delaware corporation
(“Amedica”), and Rodney Plaster, M.D. (“Plaster”). 
  
 RECITALS: 
  
 A. Amedica is in
the business of designing, developing and selling various products and applications for medical and biomedical uses and from various materials, including the use of advanced ceramic materials; 
  
 B. Amedica desires to continue to encourage the conceiving, development,
testing, providing education and dealing with novel devices for implant in or use with hip and knee reconstructive medical and surgical procedures (“Devices”), whether manufactured from ceramic materials or other materials; 
  
 C. Plaster is an orthopedic surgeon having knowledge and expertise relating
to hip and knee reconstructive procedures; and 
  
 D. The parties
desire to enter into arrangements between the parties to assist in the future development, approval, trial and clinical use of Devices. 
  
 NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties agree and represent as follows: 
  
 1. Definitions. 
  
 For purposes of this Agreement, the following terms shall have the following definitions: 
  
 a. “Development Services” means the development and related services as requested by Amedica relating to the conceptualization, development,
testing, approval and related matters involving the Devices more fully described in Section “b” below; 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. “Devices” are exclusively limited to those designated in Schedule “A” attached
hereto and includes all ideas, discoveries, creations, improvements, know-how, inventions, designs, developments, apparatus, techniques, methods, processes, and materials, whether or not patentable, including all rights to obtain, perfect or enforce
any proprietary interests therein, pertaining to such devices as limited in Schedule A, which Plaster, whether alone or in concert with others, may conceive, reduce to practice or develop during the Term (or, if based on or related to any
confidential or proprietary information of Amedica, within [***********] after the termination of this Agreement), alone or in conjunction with another, or others, whether during or out of regular business hours, and whether at the request or upon
the suggestion of Amedica. 
  
 2. Cooperative Development
Arrangements. 
  
 The parties intend that Plaster shall
diligently perform the Development Services and provide reasonable input and expertise hereunder. The Development Services shall include, without limitation, the following: 
  
 a. Examining and reviewing the characteristics of the Devices and the nature of the materials with which the Devices are
constructed; 
  
 b. Providing expertise in ideas and testing
pertaining to the Devices, and coordination with other Amedica personnel and third-parties related to such testing, as requested by Amedica; 
  
 c. Providing guidance and assistance in the clinical details of the Devices; 
  

 2 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 d. Assisting by providing the written portions of the patent applications pertaining to the Devices as
determined by Amedica and approved by Plaster; and 
  
 e.
Assisting by providing the written portions of applications for regulatory approval for the Devices or surgical processes for their implantation or other use. 
  

3. Term and Termination. 
  
 a. The term (“Term”) of this Agreement shall commence as of the Effective Date and shall continue until the later of: 
  
 (i) Ten (10) years from the date hereof; or 
  
 (ii) The expiration of patent rights on the Devices, unless earlier
terminated as provided hereunder. 
  
 b. Either party has the
right to terminate this Agreement at any time upon thirty (30) days prior written notice to the other. Upon termination, Amedica’s sole obligation to Plaster will be to pay any then outstanding unpaid fees, royalties or other compensation
due Plaster under the terms of this contract and to reimburse Plaster for then outstanding reimbursable expenses. Royalty payments rightfully due Plaster will continue being paid by Amedica to Plaster or his designated beneficiary after the
termination of this agreement. Further, Plaster will have the option to sell any and all Amedica stock options then owned by Plaster back to Amedica at the market value per share. 
  
 4. Compensation for Assignment and Sale of Proprietary Rights. 
  
 a. As full consideration for the Development Services related solely to
[***************************************] and any assignment of right in [******************] related to [*********************] to Amedica pursuant to Section 9 hereof, Amedica shall pay Plaster the total of the following:

  
 (i) Plaster shall, in the form of royalty or similar
payments, payable on a monthly basis, receive [********] of the Net After-Tax Profits for the [*******************************] from Amedica; provided, that this is subject to the provisions of Subsection 4(d) below. 
  

 3 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. As full consideration for the Development Services related solely to the
[*******************************] and any assignment of right in Devices related to the [*******************************], Amedica pursuant to Section 9 hereof, shall pay Plaster the total of the following: 
  
 (i) Plaster shall, in the form of royalty or similar payments, payable on a
monthly basis, receive a total of [********] of the Net After-Tax Profits; provided, that this is subject to the provisions of Subsection 4(d) below. 
  
 c. As full consideration for the Development Services related solely to the [*******************************] and any assignment of right in
Devices related to the, [*******************************], Amedica pursuant to Section 9 hereof, shall pay Plaster the total of the following: 
  
 (i) Plaster shall, in the form of royalty or similar payments, payable on a monthly basis, receive a total of [********] of the Net After-Tax
Profits; provided, that this is subject to the provisions of Subsection 4(d) below. 
  
 d. “Net After-Tax Profits” is defined as that portion of profits received by Amedica attributable to the sale of Devices, after deducting from all gross proceeds from such sales the costs and expenses
attributable to the development, testing, marketing and sale of the Devices (but not including any Amedica overhead or expenses unrelated to the Devices), and less all sales, use, occupation or excise taxes and all income taxes applicable to income
generated from the Devices. 
  

 4 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 e. Upon Plaster’s death, or upon letters from two independent physicians that Plaster is disabled
and unable to perform the nature of the Development Services hereunder, this Agreement shall terminate as to Plaster; provided, that Plaster or Plaster’s designated beneficiary, shall continue to be entitled to receive the royalties as provided
herein, applicable to all Devices completed for marketing prior to the date of death or disability. 
  
 f. Notwithstanding any provision herein to the contrary, income used for calculating royalties payable to Plaster hereunder shall not include any sales
attributable to the use of any Devices by any hospital or surgical center where Plaster (or a partner, shareholder, employee or contracting physician) currently practices medicine. No provision under this Agreement, either overtly or covertly,
directly or indirectly, requires or contemplates that Plaster make any recommendations to Plaster’s patients or health care facilities with respect to Amedica’s Devices or other products. There shall be no adjustment to the percentage of
royalties, or the rate of any other compensation, resulting from the presence of or absence of, any recommendations of Amedica’s Devices or other products to Plaster’s patients or health care facilities by Plaster. 
  
 g. Amedica shall maintain separate accountings relating to the Devices.
Plaster shall, at all times, have reasonable access to examine Amedica’s books and records relating to the Devices. 
  
 h. Plaster acknowledges that the payment provisions of this Section 4 represents the sole agreement between the parties with regard to Plaster’s
compensation for all Development Services and any assignment of rights to the Devices; and Amedica shall not be 

  

 5 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
obligated to make, or otherwise be liable for, any additional payment of compensation or reimbursement of expenses with regard to Development Services or the
Devices or other similar type payment. It is the parties’ intent that this Agreement provide for the “sale or exchange of a capital asset” by Plaster to Amedica under Internal Revenue Code Section 1235 entitled “Sale or
Exchange of Patents,” and that all payments made to Plaster hereunder shall be taxed as long-term capital gains. Nothing in this Agreement to the contrary shall imply that the parties intend that the payments to Plaster hereunder shall be for
anything other than the transfer of all proprietary rights that Plaster may have in the Devices. Amedica is making no warranties or representations, however, as to ultimate taxability of the payments to Plaster hereunder. 
  
 5. Exclusivity. 
  
 Amedica acknowledges that Plaster has other professional business and
investment dealings in addition to his responsibilities under this Agreement and that Plaster will not be required to devote his time exclusively to his responsibilities hereunder. Notwithstanding any provision herein to the contrary, Plaster agrees
that during the Term, Amedica shall have the exclusive rights to the Devices. 
  
 6. Confidentiality. 
  
 a. Both during the Term and following termination of this Agreement for any reason, except as necessary for the performance of the Development Services hereunder, Plaster shall not, at any time or in any manner, directly or indirectly, use,
divulge, disclose or communicate to any third-person or entity any information that was disclosed to or developed by Plaster during the course of performing the Development Services and which is not generally available to the public, including,
without limiting the generality of the foregoing: information regarding matters affecting or relating to Amedica’s business or its Devices; the nature of 

  

 6 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
Amedica’s properties or products, whether developed or under development; the identity of Amedica’s customers; prices which Amedica obtains or has
obtained with respect to its products or services; information as to Amedica’s discussions, negotiations and/or dealings with actual or potential third-party buyers, investors, licensees or co-venturers; Amedica’s costs, overhead or profit
margin; or Amedica’s operational methods or its business plans and processes. All material as such will be labeled “confidential”. 
  
 b. Records; Promptly following termination of this Agreement, Plaster shall deliver to Amedica any and all property of Amedica which may be in his
possession including products, materials, memoranda, notes, records, reports, writings, drawings, diskettes, models and other materials or other documents or photocopies of the same in any tangible form whatsoever constituting confidential or
proprietary information of Amedica, and any of the foregoing in intangible form. 
  
 7. Covenant Not to Compete. 
  
 a. Certain Acknowledgments and Agreements. Plaster recognizes and acknowledges the competitive and proprietary nature of Amedica’s business operations. Plaster acknowledges and agrees that a business will
be deemed competitive with Amedica if it engages in a line of business in which it develops, manufactures or sells any products provided or offered by Amedica or any similar ceramic products to those defined in Schedule “A”. 
  
 b. Plaster agrees that during the Term and for an additional
[********] after termination of this Agreement (which period shall be tolled during the period of any violation or breach of any of the provisions hereof and for a period of [********] thereafter), whether such termination is voluntary or
involuntary, Plaster shall not: 
  
 (i) For his benefit, or on
behalf of any other person or entity, directly or indirectly, as principal, agent, stockholder, employee, consultant, representative or in any other capacity, own, manage, operate or control, or be concerned, connected or employed by, or otherwise
associate in any manner with, engage in or have a financial interest in any Competitive Business dealing, manufacturing or having an interest in the devices listed in Schedule “A” anywhere in the continental United States of America (the
“Restricted Territory”), except that nothing contained herein shall preclude Plaster from purchasing or owning securities of any such business if such securities are publicly traded, and provided that his holdings do not exceed one percent
(1%) of the issued and outstanding securities of any class of securities of such business; or 
  

 7 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 (ii) Either individually or on behalf of or through any third party, solicit, divert or appropriate or
attempt to solicit, divert or appropriate, any known customers or patrons of Amedica; or 
  
 (iii) Either individually or on behalf of or through any third party, directly or indirectly, solicit, entice or persuade or attempt to solicit, entice or persuade any other employees of or consultants to Amedica or
any present or future parent, subsidiary or affiliate of Amedica to leave the services of Amedica or any such parent, subsidiary or affiliate for any reason. 
  
 c. Reasonableness of Restrictions. Plaster further recognizes and acknowledges that: 
  
 (i) The restrictions in this Section 7 are reasonable in relation to the skills which represent his principal salable
asset both to Amedica and to any prospective employers; and 
  

 8 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 (ii) The geographical scope of the provisions of this Section 7 is reasonable, legitimate and fair
to Plaster in light of Amedica’s need to market its services and sell its products worldwide in order to have a sufficient customer base to make Amedica’s business profitable and in light of the limited restrictions on the type of
employment prohibited herein compared to the types of employment for which Plaster is qualified to earn his livelihood. 
  
 d. Survival of Acknowledgments and Agreements. The acknowledgments and agreements set forth in this Section 7 shall survive the expiration or
termination of this Agreement. 
  
 8. Ownership of Ideas,
Copyrights and Patents. 
  
 a. Disclosure of
Devices. Plaster agrees that he will promptly disclose all Devices to Amedica and that he will not publish any Devices, or any information with regard thereto, without the prior written consent of Amedica. 
  
 b. Property of Amedica. Amedica shall have the sole and exclusive
right, even as to Plaster, to prepare, file, prosecute, obtain and maintain any and all patents and patent applications claiming any Devices. All Devices shall be the sole and exclusive property of Amedica and, subject to payment pursuant to the
provisions of Section 3 hereof, Plaster hereby assigns to Amedica all of his right, title and interest in and to all of the Devices unless Amedica fails to commence the manufacture, marketing or distribution of the Devices within [***********]
of development. Plaster further agrees to use his best efforts to ensure that no Devices will violate or infringe upon any right, patent, copyright, trademark or right of privacy, or constitute libel or slander against or violate any other rights of
any person, firm or corporation. 
  
 c. Prior Rights.
Plaster has attached hereto as Schedule “B” 
  

 9 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 (i) A list of all proprietary concepts and inventions in which he has any right, title, or interest as
of the date of his execution of this Agreement (“Prior Rights”); and 
  
 (ii) A list of all Prior Rights made, conceived, or developed, in whole or in part, by Plaster prior to the date of his execution of this Agreement, and Plaster represents that Schedule “B” is a complete and
accurate list of all Prior rights. 
  
 d. Cooperation.
Plaster hereby agrees to willfully cooperate with Amedica, its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect Amedica’s rights in and to any Devices, including, but not limited
to, performing all acts deemed necessary or desirable by Amedica (both during the Term and for a period of [***********] after expiration of this Agreement) and joining in any proceeding to obtain letters patent, copyrights, trademarks or other
legal rights of the United States of America and of any and all other countries to Devices; provided, that, Amedica will bear the expense of all such proceedings, Plaster hereby agrees that any patent or other legal right covering any Device issued
to Plaster personally, shall be assigned by Plaster to Amedica without charge by Plaster, except as specifically provided under Section 3 hereof. 
  
 e. Works Made For Hire. Without limiting the foregoing, Plaster further acknowledges that all original works of authorship made by Plaster after
the execution of this agreement, whether alone or jointly with others in the performance of the Development Services and which are protectable by copyright are “works made for hire” within the meaning of the United States Copyright Act, 17
U.S.C. § 101, as amended, the copyright of which shall be owned solely, completely and exclusively by Amedica. If any Device is considered to be work not included in the categories of work covered by the United States Copyright Act, 17 U.S.C.
§ 101, as amended, such work shall be owned solely by, or hereby assigned or transferred completely and exclusively to Amedica. 
  

 10 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 9. Representations and Warranties Regarding Prior Work and Legal Obligations. 

 
 a. Plaster hereby represents and warrants that he has no commitments or
obligations with any prior employer or any other person or entity that would restrict his ability to perform the Development Services, or is inconsistent with this Agreement and Plaster hereby agrees to indemnify and hold Amedica harmless against
loss, damage, liability or expense arising from any claim based upon circumstances alleged to be inconsistent with such representation and warranty. 
  
 b. Plaster represents that he has been advised by Amedica that at no time should he divulge to, or use for the benefit of, Amedica any trade secret or
confidential or proprietary information of any previous employer. Plaster acknowledges that he has not divulged or used any such information for the benefit of Amedica. 
  
 c. Plaster represents that he has not and will not misappropriate any invention that he maintained any part in creating
while working for any former employer. 
  
 d. Plaster acknowledges
that Amedica is basing important business decisions on these representations, and affirms that all of the statements included herein are true. 
  
 10. Equitable Remedies. 
  
 Plaster acknowledges that the breach of the provisions of Sections 6, 7, 8 and 9 above shall constitute irreparable damage to Amedica and, accordingly,
Amedica may, in addition to all other available remedies under law and equity, obtain injunctive relief upon an alleged violation of such Sections pending resolution on the merits of any claims raised by Amedica hereunder. 
  

 11 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 11. Stock Option Arrangements. 
  
 As further consideration hereunder, the parties agree in good faith to
negotiate an agreement granting Plaster certain rights to obtain options for the purchase of Amedica stock. The nature, amount and terms of such options shall be agreed upon by the parties in good-faith as soon as reasonably possible. 
  
 12. Development Agreement Only. 
  
 This Agreement constitutes a development agreement only. Nothing herein is
intended, nor shall it be construed, to create any employer/employee arrangement, partnership arrangement or other relationship between or among the parties except as expressly provided herein; and nothing herein is intended to grant to either party
any right or interest in or to the assets, business or interests of the other party, nor the right to bind the other party except as expressly herein provided. 
  

13. Compliance with Laws and Regulations. 
  
 The parties, at all times, shall interpret and apply the provisions of this Agreement strictly in accordance with all applicable laws and regulations,
including, but not limited to, the so-called Stark federal anti-referral law and all Medicare and Medicaid laws and regulations. If any provision of this Agreement is found, by any applicable court or government agency, to be in conflict with any
applicable law or regulation, the provisions of such law or regulation shall govern; and the interpretation and operation under this Agreement shall be modified accordingly. 
  

 12 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 14. Indemnification by Amedica. 
  
 a. Amedica will indemnify and hold Plaster harmless from any and all claims,
costs, judgments and expenses involving: 
  
 (i) Any claim that
any Device infringes or interferes with any patent or other proprietary claim of any third-party; 
  
 (ii) To the extent claimed or proven to be solely due to Device design or manufacturing defect (including reasonable attorneys’ fees) of whatever
sort based on claims of product design or manufacturing defects whether sounding in negligence, strict liability at law, contract or statutory violation; and 
  
 (iii) Any breach by Amedica of any provision of this Agreement. 
  

b. Any indemnification provided by Amedica hereunder shall not apply to any claim insofar as that claims: 
  
 (i) Relates to a professional medical liability or malpractice claim
brought against Plaster for professional acts or omissions in connection with the medical care or treatment associated with a Device; 
  
 (ii) Arises from any breach by Plaster of any provision of this Agreement; or 
  
 (iii) Arises from any knowing submission by Plaster of false data to Amedica or from any other intentional wrongdoing by
Plaster. 
  
 c. Promptly upon Plaster’s receipt of
information concerning the commencement of any third-party claim, demand, action, suit or proceeding (collectively, “Action”) which is the subject of indemnification hereunder, Plaster shall notify Amedica in writing of the commencement of
the Action. Any failure to provide such prompt notice shall 

  

 13 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
relieve Amedica of its indemnification obligations to the extent Amedica has been materially prejudiced by such failure. Amedica may select counsel at its
own expense and control the defense of such indemnity claim and Plaster may participate jointly with Amedica in such defense, at Plaster’s expense, in which event the parties shall reasonably cooperate with each other subject, however, to
Amedica’s ultimate control of the defense. With respect to any Action relating solely to the payment of money damages, Amedica shall have the sole right to defend, settle, or otherwise dispose of such claim on such terms as Amedica, in its sole
discretion, shall deem appropriate; provided, that Amedica shall provide reasonable evidence of its ability to pay any damages claimed. If the Action involves any claim in which Plaster would become subject to injunctive relief or to other equitable
relief, or Plaster’s business would be adversely affected in any manner, Amedica shall settle that claim only upon the written consent of Plaster, which shall not be unreasonably withheld. 
  
 15. Indemnification by Plaster. 
  
 Except to the extent that any such claims arise through the wrongful act or
neglect of Amedica, Plaster will indemnify and hold Amedica harmless from any and all claims, costs, judgments and expenses arising from any breach by Plaster of any provision of this Agreement. 
  
 16. General. 
  
 a. Notices. All notices required or permitted to be given to a party
hereunder shall be mailed by certified mail or registered mail, postage prepaid, to that party’s address set forth on the signature page of this Agreement (or to such other address specified in writing). 
  
 b. Default. If either party defaults upon any of the covenants or
provisions herein, the defaulting party shall pay all costs and attorneys’ fees incurred by the other party in enforcing its rights arising hereunder. 
  

 14 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 c. Governing Law and Venue. This Agreement shall be interpreted, performed and enforced according
to the laws of Utah. Venue for any action hereof shall lie with the Third Judicial District Court of the State of Utah for the United States District Court for the District of Utah, Central Division. 
  
 d. Unenforceable Provision. If any provision of this Agreement is
deemed unenforceable by any court of competent jurisdiction, the remaining provisions shall nonetheless be enforceable according to their terms. Further, if any provision is held to be over broad as written, such provision shall be deemed amended to
narrow its application to the extent necessary to make the provision enforceable according to applicable law and shall be enforced as amended. 
  
 e. Assignment. Amedica may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of
Amedica’s business or that aspect of Amedica’s business in which Plaster is principally involved. Plaster’s rights and obligations under this Agreement may not be assigned by Plaster without the prior written consent of Amedica.

  
 f. Benefit. All statements, representations,
warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to
create any rights or obligations except between the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this Agreement, other than any future parent, subsidiary or affiliate of Amedica. 
  
 g. Entire Agreement. This Agreement embodies the entire agreement and
understanding between and among the parties hereto with respect to the subject matter hereof 

  

 15 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty,
covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. 
  
 h. Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by
written agreement executed by the parties hereto. 
  
 i.
Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such
waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and
for the purpose for which it was given, and shall not constitute a continuing waiver or consent. 
  
 j. Construction. The parties have participated equally in the formation of this Agreement and the language of this Agreement will not be
presumptively construed against either party. 
  
 k.
Counter. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

  
 l. Section Numbers and Headings. The Section and
Subsection headings and numbers used herein are for purposes of convenience and shall not be considered in the interpretation of this Agreement. 
  

 16 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF this 12th day of December, 2005. 
  
 AMEDICA ADDRESS 
 AMEDICA CORP. 
 A DELAWARE CORPORATION 
  
 Amedica Corporation 
 615 Arapeen Drive, Suite 302 
 Salt Lake City, UT 84108 
  

	
	 /s/ Eugene B. Jones

	 Eugene B. Jones

	 Vice President Finance & CFO

  
 PLASTER ADDRESS 
 Rodney Plaster, M.D. 
 [********************] 
 [********************] 
  

	
	 /s/ Rodney Plaster

	 RODNEY PLASTER, M.D.

  

 17 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE A 
  
 Devices: 
  
 The Devices consist of the following, [**************************************]: 
  

	 	1.	 	[*************************]; 

  

	 	2.	 	[*************************]; and 

  

	 	3.	 	[*************************]. 

  

 A-1 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE B 
  
 Prior Rights: 
  

	 	1.	 	[*******************************] 

  

 19 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]